GSK FINANCE (NO 2) LIMITED
Get an alert when GSK FINANCE (NO 2) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-06 (in 5mo)
Last made up 2025-09-22
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£20B
+11.6% vs 2023
Employees
0
Average over period
Profit before tax
-£20M
+75.8% vs 2023
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£83,027,428 | -£20,118,606 | |
| Profit before tax | -£83,027,428 | -£20,118,606 | |
| Net profit | -£87,103,781 | -£13,762,046 | |
| Cash | — | — | |
| Total assets less current liabilities | £18,585,467,754 | £20,661,471,460 | |
| Net assets | £17,859,481,097 | £19,927,742,031 | |
| Equity | £17,859,481,097 | £19,927,742,031 | |
| Average employees | 0 | 0 | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | -0.4% | -0.1% | |
| Gearing (liabilities / total assets) | 13.4% | 3.7% | |
| Current ratio | 0.01x | 0.71x | |
| Interest cover | -0.93x | -0.19x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101 Reduced Disclosure Framework
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Having assessed the principal risks of the Company and other matters the Directors are of the opinion that the current level of activity remains sustainable. The Directors in their considerations have included the accessibility of additional capital and the potential risk to liquidity. The Directors have considered the Company's ability to continue as a going concern for a minimum of twelve months from the date of signing of these financial statements. The Directors have taken into account that as part of the Group, the Company has already received the necessary letter of support from GlaxoSmithKline Finance plc and can take actions to ensure business continuity through operational channels, as well as the ability to manage variable costs. On the basis of those considerations, the Directors believe that it remains appropriate to adopt the going concern basis of accounting in preparing the financial statements.”
Group structure
- GSK FINANCE (NO 2) LIMITED · parent
- Affinivax, Inc. 100%
- Aiolos Bio, Inc 100%
- Aiolos Bio Limited 100%
- Cellzome GmbH 100%
- Colleen Corporation 100%
- Corixa Corporation 100%
- Elsie Biotechnologies, Inc. 100%
- Glaxochem (UK) Unlimited 43.14%
- GlaxoSmithKline Biologicals S.A.S. 100%
- GlaxoSmithKline Biologicals SA 20.4%
- GlaxoSmithKline Brasil Limitada 39.57%
- GlaxoSmithKline Capital Inc. 100%
- GlaxoSmithKline Chile Farmaceutica Limitada 100%
- GlaxoSmithKline Holdings (Americas) Inc. 100%
- GlaxoSmithKline International Limited 20.4%
- GlaxoSmithKline LLC 100%
- GlaxoSmithKline SL LLC 100%
- GlaxoSmithKline SL LP 100%
- GSK Equity Investments, Limited 100%
- Human Genome Sciences, Inc. 100%
- J&J Technologies, LC 100%
- Laboratorios Stiefel Ltda. 4.76%
- SmithKline Beecham (Investments) Limited 44.96%
- Stiefel Laboratories (U.K.) Ltd 37.18%
- Stiefel Laboratories, Inc. 100%
- Stiefel Research (Australia) Holdings Pty Ltd 100%
- Stiefel Research Australia Pty Ltd 100%
- Stiefel West Coast LLC 100%
- Strebor Inc. 100%
- Tesaro Bio GmbH 100%
- Tesaro Bio Netherlands B.V 100%
- TESARO Development, Ltd. 100%
- Tesaro UK Limited 100%
- Tesaro, Inc. 100%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| WHYTE, Victoria Anne | Secretary | 2018-12-12 | — | — |
| BROWN, Julie Belita | Director | 2023-05-01 | Mar 1962 | British |
| WALKER, Adam | Director | 2018-12-12 | Nov 1967 | British |
| WOODTHORPE, Timothy John | Director | 2026-03-02 | Jan 1979 | British |
| EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Director | 2018-12-12 | — | — |
| THE WELLCOME FOUNDATION LIMITED | Corporate Director | 2018-12-12 | — | — |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DINGEMANS, Simon Paul | Director | 2018-12-12 | 2019-05-01 |
| MACKAY, Iain James | Director | 2019-05-01 | 2023-05-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Glaxosmithkline Finance Plc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-12-12 | Active |
Filing timeline
Last 20 of 46 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-08 | SH01 | capital | Capital allotment shares | |
| 2026-03-03 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-10 | AA | accounts | Accounts with accounts type full | |
| 2024-10-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-09-27 | SH01 | capital | Capital allotment shares | |
| 2024-09-23 | CH01 | officers | Change person director company with change date | |
| 2024-09-23 | CH03 | officers | Change person secretary company with change date | |
| 2024-09-17 | CH01 | officers | Change person director company with change date | |
| 2024-09-11 | CH02 | officers | Change corporate director company with change date | |
| 2024-09-11 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2024-09-11 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-07-18 | AD02 | address | Change sail address company with new address | |
| 2024-07-16 | AA | accounts | Accounts with accounts type full | |
| 2023-10-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-07-24 | AA | accounts | Accounts with accounts type full | |
| 2023-06-27 | SH01 | capital | Capital allotment shares | |
| 2023-05-11 | AP01 | officers | Appoint person director company with name date | |
| 2023-05-11 | TM01 | officers | Termination director company with name termination date | |
| 2022-10-05 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 2
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
+11.6%
£17,859,481,097 £19,927,742,031
-
Employees
—
Not reported
-
Operating profit
+75.8%
-£83,027,428 -£20,118,606
-
Profit before tax
+75.8%
-£83,027,428 -£20,118,606
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers